Angiex, a biotech company specialising in solid cancers, has begun patient dosing for its Phase I clinical trial of AGX101 for use in patients with solid tumours.
The first-in-class TM4SF1-directed antibody-drug conjugate (ADC) works through eliminating tumour blood vessels, killing metastatic tumour cells and directing the immune system to recognise the cancer.
Abzena is providing the clinical material for this study, and has also supported AGX101’s development through linker payload design and synthesis, as well as bioconjugation, cGMP manufacturing and process development services.
Angiex’s co-founder and CEO, Paul Jaminet, commented: “Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. Both companies have extensive expertise in their respective fields and an aligned mission, and we look forward to continuing our partnership to ensure that AGX101 is available to meet the needs of clinical cancer patients.”
Matt Stober, CEO of Abzena, said: “The Abzena team is proud to have helped Angiex achieve this milestone. Our unique ability to support Angiex with a fully integrated approach allowed us to de-risk and rapidly progress AGX101 into the clinic for patient dosing. We will continue supporting Angiex with our extensive ADC expertise and integrated capabilities to accelerate the development timeline of AGX101, and ultimately get this life-changing treatment to cancer patients faster.”
The Phase I study will assess the tolerability, safety and efficacy of AGX101 as a monotherapy, and will measure doses up to 10mg/kg in a patient population with solid tumours.
[Photo credit: Abzena]
